Pharmacological MRI (phMRI) Monitoring of Treatment in Hemiparkinsonian Rhesus Monkeys

Overview

Journal Cell Transplant

Specialties Cell Biology
General Surgery

Date 2008 Jun 5

PMID 18522244

Citations 9

Authors

Liming Luan

Feng Ding

Yi Ai

Anders Andersen

Peter Hardy

Eric Forman

Greg A Gerhardt

Don M Gash

Richard Grondin

Zhiming Zhang

Affiliations

Soon will be listed here.

Abstract

There is a great need for the development of noninvasive, highly sensitive, and widely available imaging methods that can potentially be used to longitudinally monitor treatment of Parkinson's disease (PD). Here we report the monitoring of GDNF-induced functional changes of the basal ganglia in hemiparkinsonian monkeys via pharmacological MRI measuring the blood oxygenation level-dependent (BOLD) response to a direct dopamine agonist (apomorphine, APO). After testing BOLD responsiveness to APO in their normal state, two additional scans were taken with the same dose of APO stimulation after induced parkinsonism. Then all animals were chronically treated with GDNF for 18 weeks by a programmable pump and catheter system. The catheter was surgically implanted into the right putamen and connected to the pump via flexible polyurethane tubing, phMRI scans were taken at both 6 and 18 weeks while they received 22.5 microg of GDNF per day. In addition, behavioral changes were monitored throughout the entire study. The primary finding of this study was that APO-evoked activations in the DA denervated putamen were attenuated by the chronic intraputamenal infusion of GDNF accompanied by improvements of parkinsonian features, movement speed, and APO-induced rotation compared to data collected before the chronic GDNF treatment. The results suggest that phMRI methods in combination with administration of a selective DA agonist may be useful for monitoring neurorestorative therapies in PD patients in the future.

Citing Articles

MRI monitoring of macaque monkeys in neuroscience: Case studies, resource and normative data comparisons.

Balezeau F, Nacef J, Kikuchi Y, Schneider F, Rocchi F, Muers R Neuroimage. 2021; 230:117778.

PMID: 33497775 PMC: 8063182. DOI: 10.1016/j.neuroimage.2021.117778.

Validations of apomorphine-induced BOLD activation correlations in hemiparkinsonian rhesus macaques.

Quintero J, Ai Y, Andersen A, Hardy P, Grondin R, Guduru Z Neuroimage Clin. 2019; 22:101724.

PMID: 30822717 PMC: 6396014. DOI: 10.1016/j.nicl.2019.101724.

Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic Neurons Recover Locomotive Defects of Nonhuman Primate Models of Parkinson's Disease.

Wang Y, Zhu W, Wu M, Wu Y, Liu Z, Liang L Stem Cell Reports. 2018; 11(1):171-182.

PMID: 29910127 PMC: 6067059. DOI: 10.1016/j.stemcr.2018.05.010.

Objectively measuring effects of electro-acupuncture in parkinsonian rhesus monkeys.

Zhang R, Andersen A, Hardy P, Forman E, Evans A, Ai Y Brain Res. 2017; 1678:12-19.

PMID: 29017909 PMC: 5714666. DOI: 10.1016/j.brainres.2017.10.006.

Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson's Disease (PD).

Tuite P Brain Sci. 2017; 7(6).

PMID: 28621758 PMC: 5483641. DOI: 10.3390/brainsci7060068.

References

Zhang Z, Andersen A, Avison M, Gerhardt G, Gash D . Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys. Brain Res. 2000; 852(2):290-6. DOI: 10.1016/s0006-8993(99)02243-x. View

Ai Y, Markesbery W, Zhang Z, Grondin R, Elseberry D, Gerhardt G . Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol. 2003; 461(2):250-61. DOI: 10.1002/cne.10689. View

Bjorklund A, Lindvall O . Parkinson disease gene therapy moves toward the clinic. Nat Med. 2000; 6(11):1207-8. DOI: 10.1038/81291. View

Yasuhara T, Date I . Intracerebral transplantation of genetically engineered cells for Parkinson's disease: toward clinical application. Cell Transplant. 2007; 16(2):125-32. View

Andersen A, Zhang Z, Barber T, Rayens W, Zhang J, Grondin R . Functional MRI studies in awake rhesus monkeys: methodological and analytical strategies. J Neurosci Methods. 2002; 118(2):141-52. DOI: 10.1016/s0165-0270(02)00123-1. View

Ul Haq I, LeWitt P, Fernandez H . Apomorphine therapy in Parkinson's disease: a review. Expert Opin Pharmacother. 2007; 8(16):2799-809. DOI: 10.1517/14656566.8.16.2799. View

Yahr M . Levodopa. Ann Intern Med. 1975; 83(5):677-82. DOI: 10.7326/0003-4819-83-5-677. View

Ungerstedt U, LJUNGBERG T, Schultz W . Dopamine receptor mechanisms: behavioral and electrophysiological studies. Adv Biochem Psychopharmacol. 1978; 19:311-21. View

Tomac A, Lindqvist E, Lin L, Ogren S, Young D, Hoffer B . Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995; 373(6512):335-9. DOI: 10.1038/373335a0. View

10.

Kordower J, Emborg M, Bloch J, Ma S, Chu Y, Leventhal L . Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000; 290(5492):767-73. DOI: 10.1126/science.290.5492.767. View

11.

Grondin R, Cass W, Zhang Z, Stanford J, Gash D, Gerhardt G . Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci. 2003; 23(5):1974-80. PMC: 6741972. View

12.

Beck K, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen R . Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 1995; 373(6512):339-41. DOI: 10.1038/373339a0. View

13.

Soderstrom K, OMalley J, Steece-Collier K, Kordower J . Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15(3):251-65. DOI: 10.3727/000000006783982025. View

14.

Ovadia A, Zhang Z, Gash D . Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging. 1995; 16(6):931-7. DOI: 10.1016/0197-4580(95)02012-8. View

15.

Gill S, Patel N, Hotton G, OSullivan K, McCarter R, Bunnage M . Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003; 9(5):589-95. DOI: 10.1038/nm850. View

16.

Lang A, Gill S, Patel N, Lozano A, Nutt J, Penn R . Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006; 59(3):459-66. DOI: 10.1002/ana.20737. View

17.

de la Fuente-Fernandez R, Stoessl A . Parkinson's disease: imaging update. Curr Opin Neurol. 2002; 15(4):477-82. DOI: 10.1097/00019052-200208000-00012. View

18.

Zhang Z, Andersen A, Grondin R, Barber T, Avison R, Gerhardt G . Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake rhesus monkeys. Neuroimage. 2001; 14(5):1159-67. DOI: 10.1006/nimg.2001.0902. View

19.

Steward C, Marsden C, Prior M, Morris P, Shah Y . Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (Berl). 2005; 180(4):687-704. DOI: 10.1007/s00213-005-2213-7. View

20.

Dagher A, Nagano-Saito A . Functional and anatomical magnetic resonance imaging in Parkinson's disease. Mol Imaging Biol. 2007; 9(4):234-42. DOI: 10.1007/s11307-007-0089-0. View